A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
National Cancer Institute, Naples
Jinan Military General Hospital
Jinan Military General Hospital
Roswell Park Cancer Institute
Tongji Hospital
Mirati Therapeutics Inc.
Intergroupe Francophone de Cancerologie Thoracique
Nanjing Leads Biolabs Co.,Ltd
Elevar Therapeutics
Second Affiliated Hospital of Soochow University
Suzhou Genhouse Bio Co., Ltd.
Fujian Cancer Hospital
Hebei Medical University Fourth Hospital
MedSIR
Zhujiang Hospital
Peking University
Grupo Español de Investigación en Cáncer de Ovario
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
LaNova Medicines Limited
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanjing First Hospital, Nanjing Medical University
Shanghai Hengrui Pharmaceutical Co., Ltd.
Beidahuang Industry Group General Hospital
Jiangsu HengRui Medicine Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
AlaMab Therapeutics (Shanghai) Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mateon Therapeutics
The First Affiliated Hospital of Zhengzhou University